IDEAS home Printed from https://ideas.repec.org/a/eee/hepoli/v44y1998i3p253-260.html

What is Germany's experience on reference based drug pricing and the etiology of adverse health outcomes or substitution?

Author

Listed:
  • Schneeweiss, Sebastian
  • Schoffski, Oliver
  • Selke, Gisbert W

Abstract

No abstract is available for this item.

Suggested Citation

  • Schneeweiss, Sebastian & Schoffski, Oliver & Selke, Gisbert W, 1998. "What is Germany's experience on reference based drug pricing and the etiology of adverse health outcomes or substitution?," Health Policy, Elsevier, vol. 44(3), pages 253-260, June.
    • Handle: RePEc:eee:hepoli:v:44:y:1998:i:3:p:253-260
    as

    Download full text from publisher

    File URL: http://www.sciencedirect.com/science/article/pii/S0168-8510(98)00023-2
    Download Restriction: Full text for ScienceDirect subscribers only
    ---><---

    As the access to this document is restricted, you may want to

    for a different version of it.

    References listed on IDEAS

    as
    1. von der Schulenburg, J. -Matthias Graf, 1997. "Management of cost and utilization of pharmaceuticals in Germany," Health Policy, Elsevier, vol. 41(Supplemen), pages 45-53, September.
    2. Abel-Smith, Brian & Mossialos, Elias, 1994. "Cost containment and health care reform: a study of the European Union," Health Policy, Elsevier, vol. 28(2), pages 89-132, May.
    3. Kane, Nancy M. & Saltman, Richard B., 1997. "Comparative experience in home care and pharmaceutical policy," Health Policy, Elsevier, vol. 41(Supplemen), pages 1-7, September.
    4. Kane, Nancy M., 1997. "Pharmaceutical cost containment and innovation in the United States," Health Policy, Elsevier, vol. 41(Supplemen), pages 71-89, September.
    5. Ljungkvist, Mats-Olof & Andersson, David & Gunnarsson, Bo, 1997. "Cost and utilisation of pharmaceuticals in Sweden," Health Policy, Elsevier, vol. 41(Supplemen), pages 55-69, September.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Bergstrom, Gina & Karlberg, Ingvar, 2007. "Decentralized responsibility for costs of outpatient prescription pharmaceuticals in Sweden: Assessment of models for decentralized financing of subsidies from a management perspective," Health Policy, Elsevier, vol. 81(2-3), pages 358-367, May.
    2. Fabiano, Valentina & Mameli, Chiara & Cattaneo, Dario & Delle Fave, Antonella & Preziosa, Alessandra & Mele, Giuseppe & Clementi, Emilio & Zuccotti, Gian Vincenzo, 2012. "Perceptions and patterns of use of generic drugs among Italian Family Pediatricians: First round results of a web survey," Health Policy, Elsevier, vol. 104(3), pages 247-252.
    3. Schneeweiss, Sebastian, 2007. "Reference drug programs: Effectiveness and policy implications," Health Policy, Elsevier, vol. 81(1), pages 17-28, April.
    4. Garattini, Livio & Tediosi, Fabrizio, 2000. "A comparative analysis of generics markets in five European countries," Health Policy, Elsevier, vol. 51(3), pages 149-162, April.
    5. Lopez-Casasnovas, Guillem & Puig-Junoy, Jaume, 2000. "Review of the literature on reference pricing," Health Policy, Elsevier, vol. 54(2), pages 87-123, November.
    6. Schreyögg, Jonas & Henke, Klaus-Dirk & Busse, Reinhard, 2004. "Managing pharmaceutical regulation in Germany: Overview and economic assessment," Discussion Papers 2004/6, Technische Universität Berlin, School of Economics and Management.
    7. Andersson, Karolina & Petzold, Max Gustav & Sonesson, Christian & Lonnroth, Knut & Carlsten, Anders, 2006. "Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures?: Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986-2002," Health Policy, Elsevier, vol. 79(2-3), pages 231-243, December.
    8. Hokkanen, Joni & Kangasharju, Aki & Linnosmaa, Ismo & Valtonen, Hannu, 2012. "Generic substitution policy, prices and market structure: evidence from a quasi-experiment in Finland," Working Papers 35, VATT Institute for Economic Research.
    9. Busse, Reinhard, 1999. "Priority-setting and rationing in German health care," Health Policy, Elsevier, vol. 50(1-2), pages 71-90, December.
    10. Andersson, Karolina & Bergstrom, Gina & Petzold, Max G. & Carlsten, Anders, 2007. "Impact of a generic substitution reform on patients' and society's expenditure for pharmaceuticals," Health Policy, Elsevier, vol. 81(2-3), pages 376-384, May.
    11. Schneeweiss, Sebastian & Maclure, Malcolm & Walker, Alexander M. & Grootendorst, Paul & Soumerai, Stephen B., 2001. "On the evaluation of drug benefits policy changes with longitudinal claims data: the policy maker's versus the clinician's perspective," Health Policy, Elsevier, vol. 55(2), pages 97-109, February.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Bergstrom, Gina & Karlberg, Ingvar, 2007. "Decentralized responsibility for costs of outpatient prescription pharmaceuticals in Sweden: Assessment of models for decentralized financing of subsidies from a management perspective," Health Policy, Elsevier, vol. 81(2-3), pages 358-367, May.
    2. Lopez-Casasnovas, Guillem & Puig-Junoy, Jaume, 2000. "Review of the literature on reference pricing," Health Policy, Elsevier, vol. 54(2), pages 87-123, November.
    3. Eulàlia Dalmau & Jaume Puig, 1997. "Market structure and hospital efficiency: Evaluating potential effects of deregulation in a national health service," Economics Working Papers 214, Department of Economics and Business, Universitat Pompeu Fabra.
    4. G P Westert, 1997. "State Control and the Delivery of Health Care: A Preliminary Study in Eleven European Countries," Environment and Planning C, , vol. 15(2), pages 219-228, June.
    5. Mousnad, Mohamed Awad & Shafie, Asrul Akmal & Ibrahim, Mohamed Izham, 2014. "Systematic review of factors affecting pharmaceutical expenditures," Health Policy, Elsevier, vol. 116(2), pages 137-146.
    6. Delnoij, Diana & Brenner, Gerhard, 2000. "Importing budget systems from other countries: what can we learn from the German drug budget and the British GP fundholding?," Health Policy, Elsevier, vol. 52(3), pages 157-169, July.
    7. Liaropoulos, Lycurgus & Tragakes, Ellie, 1998. "Public/private financing in the Greek health care system: implications for equity," Health Policy, Elsevier, vol. 43(2), pages 153-169, February.
    8. Adriana Benítez-Rico & Arizbeth Pérez-Martínez & Bryan Isaac Muñóz-López & Laura Martino-Roaro & Jorge Adan Alegría-Baños & Arely Vergara-Castañeda & Alejandro Islas-García, 2023. "Medical Household Waste as a Potential Environmental Hazard: An Ecological and Epidemiological Approach," IJERPH, MDPI, vol. 20(7), pages 1-18, April.
    9. Westert, Gert P. & Lagoe, Ronald J. & Keskimaki, Ilmo & Leyland, Alastair & Murphy, Mark, 2002. "An international study of hospital readmissions and related utilization in Europe and the USA," Health Policy, Elsevier, vol. 61(3), pages 269-278, September.
    10. Andrea Riganti, 2021. "Containing costs in the Italian local healthcare market," Health Economics, John Wiley & Sons, Ltd., vol. 30(5), pages 1001-1014, May.
    11. Aletras, Vassilios & Kontodimopoulos, Nick & Zagouldoudis, Athanasios & Niakas, Dimitris, 2007. "The short-term effect on technical and scale efficiency of establishing regional health systems and general management in Greek NHS hospitals," Health Policy, Elsevier, vol. 83(2-3), pages 236-245, October.
    12. Gevers, J.M.P. & Gelissen, J.P.T.M. & Arts, W.A. & Muffels, R.J.A., 1999. "Public health care in balance : Exploring popular support for health care systems in the European Union," WORC Paper 99.12.04, Tilburg University, Work and Organization Research Centre.
    13. Elias Mossialos, 1997. "Citizens' Views on Health Care Systems in the 15 Member States of The European Union," Health Economics, John Wiley & Sons, Ltd., vol. 6(2), pages 109-116, March.
    14. Grazyna Kozun-Cieslak & Pavel Zdrazil, 2021. "Efficiency of Healthcare Systems in the European Union States – Who Performs Better – Bismarckians or Beveridgeans?," European Research Studies Journal, European Research Studies Journal, vol. 0(Special 2), pages 397-411.
    15. Liaropoulos, Lycurgus L., 1995. "Health services financing in Greece: a role for private health insurance," Health Policy, Elsevier, vol. 34(1), pages 53-62, October.
    16. Borras, Josep M. & Granados, Alicia & Escarrabill, Joan & de Lissovoy, Gregory, 1996. "Complex decisions about an uncomplicated therapy: reimbursement for long-term oxygen therapy in Catalonia (Spain)," Health Policy, Elsevier, vol. 35(1), pages 53-59, January.
    17. Martin Kenneally & Brenda Lynch, 2018. "Ageing, health status and coverage rate effects on community prescription costs in Ireland," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(5), pages 687-695, June.
    18. El Houcine Akhnif & Abdelouahab Belmadani & Awad Mataria & Maryam Bigdeli, 2024. "UHC in Morocco: a bottom-up estimation of public hospitals' financing size based on a costing database," Health Economics Review, Springer, vol. 14(1), pages 1-14, December.
    19. Eulàlia Dalmau & Jaume Puig, 1997. "Market structure and hospital efficiency: Evaluating potential effects of deregulation in a national health service," Working Papers, Research Center on Health and Economics 214, Department of Economics and Business, Universitat Pompeu Fabra.
    20. Hanna Koskinen & Elina Ahola & Leena Saastamoinen & Hennamari Mikkola & Jaana Martikainen, 2014. "The impact of reference pricing and extension of generic substitution on the daily cost of antipsychotic medication in Finland," Health Economics Review, Springer, vol. 4(1), pages 1-10, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:hepoli:v:44:y:1998:i:3:p:253-260. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu or the person in charge (email available below). General contact details of provider: http://www.elsevier.com/locate/healthpol .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.